Related Experiment Video
Updated: Feb 6, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
Hypermethylated KCNQ1 acts as a tumor suppressor in hepatocellular carcinoma
Haiyan Fan1, Meng Zhang2, Wei Liu3
1Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei Province, China.
Abstract:
Potassium (K+) channels are dysregulated in tumor tissues and functionally these channels contribute significantly to the malignant phenotypes of the cancer cells, including cell apoptosis, chemo- and radio-resistance, proliferation, and migration. However, little is known about the potential implications of K+ channels in hepatocellular carcinoma (HCC). The aim of the current study was to investigate the expression profile of KCNQ1 in HCC and assess its possible cellular implications as well as mechanism to disease progression. Using real-time qPCR and western blotting technique, we found that KCNQ1 was frequently down-regulated in HCC cell lines and tissues, and HCC patients with lower KCNQ1 expression had a poor prognosis. Specifically, DNA hypermethylation of KCNQ1 promoter resulted in its downregulation in HCC. Bioinformatic analysis indicated a regulatory role of KCNQ1 in the epithelial-to-mesenchymal transition process. Gain-of-function study showed that KCNQ1 exhibited remarkable inhibitory roles on tumor metastasis in vitro and in vivo. Mechanistically, KCNQ1 can interact with β-catenin to affect its subcellular distribution and subsequently reduce the activity of Wnt/β-catenin signaling, which further blocks the expression of its downstream targets, including c-Myc, MMP7, and CCND1. Restoration of β-catenin activity largely compromised the tumor-suppressive roles of KCNQ1 in the invasive capacity of HCC cells. In conclusion, KCNQ1 is down-regulated in HCC and may suppress HCC metastasis, which could represent a prognostic marker and promising therapeutic target for HCC.
Insights
Potassium channel KCNQ1 is downregulated in hepatocellular carcinoma (HCC), suppressing tumor metastasis. Lower KCNQ1 expression indicates poor prognosis in HCC patients, suggesting KCNQ1 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Channelopathies
Background:
- Potassium (K+) channels are implicated in cancer progression.
- Their role in hepatocellular carcinoma (HCC) remains largely unexplored.
- Dysregulation of K+ channels contributes to malignant phenotypes like proliferation and migration.
Purpose of the Study:
- Investigate KCNQ1 expression in HCC.
- Assess KCNQ1's cellular implications and role in disease progression.
- Elucidate the underlying mechanisms of KCNQ1's function in HCC.
Main Methods:
- Real-time qPCR and Western blotting to analyze KCNQ1 expression.
- DNA hypermethylation analysis of the KCNQ1 promoter.
- Bioinformatic analysis for pathway identification.
- In vitro and in vivo gain-of-function studies.
- Analysis of KCNQ1 interaction with beta-catenin and Wnt/beta-catenin signaling.
Main Results:
- KCNQ1 expression is frequently downregulated in HCC cell lines and tissues.
- Lower KCNQ1 expression correlates with poor prognosis in HCC patients.
- DNA hypermethylation of the KCNQ1 promoter causes its downregulation.
- KCNQ1 inhibits HCC metastasis in vitro and in vivo.
- KCNQ1 interacts with beta-catenin, reducing Wnt/beta-catenin signaling and downstream targets (c-Myc, MMP7, CCND1).
Conclusions:
- KCNQ1 is downregulated in HCC and suppresses tumor metastasis.
- KCNQ1 acts as a tumor suppressor by inhibiting the Wnt/beta-catenin pathway.
- KCNQ1 represents a potential prognostic marker and therapeutic target for HCC.
More Related Videos
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
08:17The In Ovo Chick Chorioallantoic Membrane CAM Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma
Published on: October 9, 2015
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drugs Acting on Autonomic Ganglia: Blockers